Literature DB >> 20634209

Tubal ligation and the risk of ovarian cancer: review and meta-analysis.

D Cibula1, M Widschwendter, O Májek, L Dusek.   

Abstract

BACKGROUND: The reduction of ovarian cancer (OC) risk in women with a history of tubal ligation (TL) has been reported repeatedly, mostly on small populations. We have aimed to provide a critical overview of the studies available to date and to conduct a meta-analysis.
METHODS: There were 40 relevant studies identified. The studies were divided into two groups for strict and extended meta-analysis, respectively. Subgroup analysis was performed for age, time dependency since TL, histological types of OC and BReast CAncer (BRCA) mutation.
RESULTS: Meta-analysis of 13 strictly selected studies showed a reduced risk of epithelial OC by 34%. The protective effect of TL was confirmed even in a subgroup of women 10-14 years after the procedure. The risk reduction was confirmed for the endometrioid (RR = 0.40) and serous (RR = 0.73) cancers but not for mucinous.
CONCLUSIONS: The review of relevant articles, as well as the meta-analysis of selected studies, yields consistent data on a significant reduction of OC risk in women who had undergone TL. The results of this meta-analysis should provide an impulse for further research on the etiology of ovarian epithelial cancers, focusing particularly on the importance of retrograde transport of endometrial cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20634209     DOI: 10.1093/humupd/dmq030

Source DB:  PubMed          Journal:  Hum Reprod Update        ISSN: 1355-4786            Impact factor:   15.610


  60 in total

1.  Fallopian tube as main source for ovarian and pelvic (non-endometrial) serous carcinomas.

Authors:  Wenxin Zheng; Oluwole Fadare
Journal:  Int J Clin Exp Pathol       Date:  2012-03-25

2.  Tubal ligation, hysterectomy and epithelial ovarian cancer in the New England Case-Control Study.

Authors:  Megan S Rice; Megan A Murphy; Allison F Vitonis; Daniel W Cramer; Linda J Titus; Shelley S Tworoger; Kathryn L Terry
Journal:  Int J Cancer       Date:  2013-07-09       Impact factor: 7.396

3.  Incidental (Prophylactic) Salpingectomy at Benign Gynecologic Surgery and Cesarean Section: a Survey of Practice in Austria.

Authors:  F L Potz; G Tomasch; S Polterauer; R Laky; C Marth; K Tamussino
Journal:  Geburtshilfe Frauenheilkd       Date:  2016-12       Impact factor: 2.915

Review 4.  The role of the fallopian tube in the origin of ovarian cancer.

Authors:  Britt K Erickson; Michael G Conner; Charles N Landen
Journal:  Am J Obstet Gynecol       Date:  2013-04-10       Impact factor: 8.661

Review 5.  Epidemiology of Patients with Ovarian Cancer with and Without a BRCA1/2 Mutation.

Authors:  Elisabete Weiderpass; Jerzy E Tyczynski
Journal:  Mol Diagn Ther       Date:  2015-12       Impact factor: 4.074

6.  Women's preferences for permanent contraception method and willingness to be randomized for a hypothetical trial.

Authors:  Adriana Piazza; Kelly Schwirian; Fiona Scott; Machelle D Wilson; Nikki B Zite; Mitchell D Creinin
Journal:  Contraception       Date:  2018-09-26       Impact factor: 3.375

Review 7.  Salpingectomy as a means to reduce ovarian cancer risk.

Authors:  Mary B Daly; Charles W Dresher; Melinda S Yates; Joanne M Jeter; Beth Y Karlan; David S Alberts; Karen H Lu
Journal:  Cancer Prev Res (Phila)       Date:  2015-01-13

8.  Prophylactic bilateral salpingectomy (PBS) to reduce ovarian cancer risk incorporated in standard premenopausal hysterectomy: complications and re-operation rate.

Authors:  J Vorwergk; M P Radosa; K Nicolaus; N Baus; J Jimenez Cruz; M Rengsberger; M Gajda; H Diebolder; I B Runnebaum
Journal:  J Cancer Res Clin Oncol       Date:  2014-02-27       Impact factor: 4.553

9.  Reproductive characteristics in relation to ovarian cancer risk by histologic pathways.

Authors:  M A Merritt; M De Pari; A F Vitonis; L J Titus; D W Cramer; K L Terry
Journal:  Hum Reprod       Date:  2013-01-12       Impact factor: 6.918

Review 10.  Hormone response in ovarian cancer: time to reconsider as a clinical target?

Authors:  Francesmary Modugno; Robin Laskey; Ashlee L Smith; Courtney L Andersen; Paul Haluska; Steffi Oesterreich
Journal:  Endocr Relat Cancer       Date:  2012-11-09       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.